<DOC>
	<DOCNO>NCT02905318</DOCNO>
	<brief_summary>The purpose study find effect new drug , palbociclib , prostate cancer look side effect treatment palbociclib . The researcher study also interested look marker may help predict patient likely help palbociclib see cancer cell respond palbociclib .</brief_summary>
	<brief_title>Palbociclib Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description>The standard usual treatment disease may chemotherapy type treatment slow spread disease relieve symptoms cancer . Palbociclib new type drug prostate cancer . Laboratory test show may help slow growth prostate cancer . Palbociclib show help patient breast cancer know drug useful treat prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<criteria>Patients must histologically confirm adenocarcinoma prostate without evidence small cell/neuroendocrine differentiation . Patients must consent blood collection screen CCND1 gain/amplification RB1 status prior enrolment central reference laboratory . Patients must clinically and/or radiologically documented disease . Patients elevate PSA eligible . All radiology study must perform within 28 day prior registration ( within 35 day negative ) . Patients must evidence either biochemical radiological disease progression set surgical medical castration : PSA progression : Minimum two rise PSA value baseline measurement interval ≥ 1 week measurement PSA must ≥2.0 ug/L Objective progression : RECIST 1.1 Soft tissue visceral disease progression Bone progression ( &gt; 2 new lesion bone scan CT ) Surgical/medical castration : Prior orchiectomy LHRH agonist/antagonist testosterone &lt; 50 ng/dL &lt; 1.7 nmol/L . LHRH agonist/antagonist therapy must maintain duration study therapy previously discontinue , must restart castrate level testosterone present . Patients must ≥18 year age . ECOG performance status 0 1 ( Appendix I ) life expectancy ≥ 6 month . Previous Therapy : Patients must recover treatmentrelated toxicity prior registration ( unless ≤ grade 1 , irreversible , consider investigator clinically significant ) . Surgery : Prior major surgery permit provide minimum 14 day elapse major surgery registration , wound heal occur . Radiation : Prior external beam radiation radium223 permit provide minimum 28 day ( 4 week ) elapse last dose registration . Limited field radiation ( example le 25 % marrow bearing bone ) palliation bone pain permit &lt; 2 week prior start study drug . Prior strontium89 time permit . Systemic Therapy : Prior systemic therapy permit outlined . Patients must recover reversible toxicity relate prior systemic therapy adequate washout prior registration follow specify Sections : Longest one follow : Two week ; The long 30 day 5 halflives investigational agent ; Standard cycle length standard therapy . Hormonal Therapy : Patients must receive prior hormonal treatment least one abiraterone acetate , enzalutamide , ARN509 TAK700 TOK001 . Prior antiandrogen therapy must discontinue least 28 day ( 42 day bicalutamide ) prior registration . Cytotoxic Therapy : A maximum one prior regimen cytotoxic chemotherapy permit . Prior treatment docetaxel , cabazitaxel mitoxantrone permit . Immunotherapy : Patients may receive prior immunotherapy ; vaccine treatment oncolytic virus permissible . Other therapy : Previous therapy CDK mTOR inhibitor allow . Prior treatment agent , tyrosine kinase target agent permissible . Systemic corticosteroid permit dose equivalent &lt; 10 mg prednisone daily ; topical application ( e.g . rash ) , inhale spray ( e.g . obstructive airway disease ) , eye drop local injection ( e.g . intraarticular ) permit . Bisphosphonates / denosumab permit treatment hypercalcemia , osteoporosis skeletalrelated event . Laboratory Requirements : Neutrophils ≥ 1.5 x 10^9/L Platelets ≥ 100 x 10^9/L Hemoglobin ≥ 100 g/L Bilirubin ≤ 1.5 x ULN ; confirm Gilbert 's bilirubin ≤ 3.0 x ULN AST ALT ≤ 1.5 x ULN ; patient liver metastasis ≤ 5.0 x ULN Serum creatinine ≤ 1.5 x ULN Creatinine clearance ≥ 50 mL/min ; Patient consent must appropriately obtain accordance applicable local regulatory requirement Patients must accessible treatment follow . Patients register trial must treat follow participate centre . In accordance CCTG policy , protocol treatment begin within 2 work day patient registration . Men childbearing potential must agree use highly effective contraceptive method treatment 90 day stop treatment father child donate sperm period . Patients history malignancy , except : adequately treat nonmelanoma skin cancer , solid tumour curatively treat evidence disease ≥ 5 year . Patients central nervous system ( CNS ) involvement unless least 4 week prior therapy completion ( include radiation and/or surgery ) AND clinically stable receive steroid and/or enzymeinducing antiepileptic medication brain metastasis . Patients serious illness medical condition could cause unacceptable safety risk would permit patient manage accord protocol . This include limited : active infection require systemic therapy ; uncontrolled/severe cardiovascular disease active know human immunodeficiency virus ( HIV ) ; Patients unable swallow oral medication and/or impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ( e.g . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . Patients history hypersensitivity palbociclib excipients . Patients treat prior CDK4/6 inhibitor , mTOR inhibitor strontium89 time require continued concurrent treatment : Systemic corticosteroid dose equivalent prednisone &gt; 10 mg daily . Topical application ( e.g . rash ) , inhale spray ( e.g . obstructive airway disease ) , eye drop local injection ( e.g . intraarticular ) allow . Any medication substance potent/strong inhibitor inducer CYP3A isoenzymes . All patient must discontinue medication least 7 day prior first dose protocol treatment ( least 14 day herbal/dietary supplement traditional Chinese medicine ) . Bisphosphonates / denosumab reason hypercalcemia , osteoporosis skeletalrelated event . Warfarin coumarinderived anticoagulant treatment , prophylaxis otherwise . Therapy heparin , low molecular weight heparin ( LMWH ) , factor X inhibitor fondaparinux allow . Other anticancer investigational agent ( except LHRH ) Patients history noncompliance medical regimen .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>